Arix Bioscience boost after Harpoon NASDAQ float
The fair value of the company's investment in Harpoon has grown by £6.2mln
Company
Arix Bioscience PLC
LON:ARIX
Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. The company collaborates with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.
180 stories · page 2 of 2
Investments and investor services
FTSE 100 joins the decline in global equities to close lower
There is not a lot of earnings news on either side of the Atlantic to drive markets higher
Arix Bioscience says Harpoon Therapeutics’ IPO pricing range would hike holding value by £4.2mln-£7.9mln
The global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding in Harpoon
Archive
Proactive news snapshot: Shield Therapeutics, ANGLE, Westminster Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Sure Ventures, Arix Bioscience, Providence Resources
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO
Harpoon Therapeutics has filed a registration statement with the US Securities and Exchange Commission relating to a proposed underwritten initial public offering
Investments and investor services
Edenville Energy falls as it notifies shareholders of plans to switch Nomad
A look at the day's major movers, including RM, MySale, Bilby, MC Mining and Bango
Archive
Proactive news snapshot: Eurasia Mining, Bango, Telit Communications …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience sees multiple advancements across portfolio
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Archive
Proactive news snapshot: Faron Pharmaceuticals, Diversified Gas & Oil, Mkango Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Interserve weak as Kier Group cash call comments spark concerns for constructors
A look at some of the London market's biggest risers and fallers on Monday
Arix Bioscience’s portfolio firm Autolus doses first patient in clinical trial of AUTO4 T-cell lymphoma therapy
PTCL is a form of cancer that arises in areas of the body such as lymph nodes, spleen, the gastrointestinal tract, and skin
FTSE 100 clings on to triple-digit gain
The Footsie looked destined to finish well off the top but still sporting a handsome gain following a weekend of deals at the G20 and Opec meetings
Investments and investor services
BigDish beefs up on bid interest but is still below its flotation price
A look at day's gliders and sliders, including Integumen, MC Mining, Intermediate Capital, Bovis Homes and other house-builders, Dart Group,Flybe, easyJet, IAG, Learning Technologies and Oilex.
Archive
Proactive news snapshot: VR Education, Bigdish, Learning Technologies …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences hails phase I success of investee company Pharmaxis
Arix is a cornerstone investor in the ASX life sciences group
Investments and investor services
FTSE 100 closes marginally higher as PM May defends draft Brexit deal
The UK's premier share index closed up around four points at 7,038, while the FTSE 250 shed almost 248 points at 18,662.
Archive
Proactive news snapshot: Sirius Minerals, MaxCyte, Arix Bioscience...
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Two Shields and Bushveld wave the flag for African mineral assets
A look at the day's winners and sinners, including Dignity, Online Blockchain, Restaurant Group, TomCo Energy, Johnston Press, GYG, Anglo African Agriculture and Carr's Group
Arix Bioscience participates in US$70mln Harpoon Series C investment round
Including the £6.1mln Series C investment, the value of Arix’s 11.3% stake in Harpoon has increased to £20.2mln
Archive
Proactive news snapshot: Mporium Group, Goldplat, Bluebird Merchant Ventures …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience’s investee company Aura Biosciences announces positive data from mid-stage eye cancer trial
The data from a phase Ib/II trial of Aura’s AU-011 eye cancer treatment show the injection doesn’t do too much damage to the surrounding healthy tissue in patients’ eyes
Archive
Proactive news snapshot: WideCells Group. Sunrise Resources, SIMEC Atlantis Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Ethernity Networks, Landore Resources, Capital Drilling …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences boost after investee company floats on NASDAQ
The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio
Essentra dips after mixed trading update, Dechra Pharma trots up on acquisition news
A look at some winners and losers in UK equity trading during Friday's session
Archive
Proactive news snapshot: Hemogenyx Pharmaceuticals, PhotonStar LED, Futura Medical …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq
As a result of the IPO, the value of Arix’s stake in LogicBio has soared to almost £23mln, including the extra investment announced today
FTSE 100 closes ahead as US earnings season gets off to strong start
The UK blue-chip index closed up almost 23 points at 7,049 - up around 0.77% on the week as a whole
Archive
Proactive news snapshot: Advanced Oncotherapy, Alba Mineral Resources, Wolf Minerals...
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience’s stake in LogicBio to soar in value once gene editing biotech floats in New York
Arix reckons the value of its stake will more than triple, but it isn’t cashing in just yet, instead it wants to buy up more shares at the IPO
Investments and investor services
Arix Biosciences forges partnership with Fred Hutch and Evotech to invest and create new drug companies focused on oncology
The partnership creates LAB591 as an academic bridge to cut down the time it takes for drug research programs to move from the lab to the market
Archive
Proactive news snapshot: Greatland Gold, European Metals, Chesnara, BigDish...
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience teams up with Takeda to invest in cancer drug developer VelosBio
Arix is investing US$11mln in VelosBio through a Series A funding round in return for an 11.2% stake in the company
FTSE 100 closes in red; Royal Mail delivers share plunge
The UK blue-chip index closed down around 14 points at 7,495 as the stronger pound weighed
Archive
Proactive news snapshot: Amryt Pharma, Directa Plus, Live Company...
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences investee company eyeing NASDAQ float
LogicBio is a specialist in genome editing that is developing drugs for rare diseases
Investments and investor services
FTSE 100 closes near flat as traders sit on hands ahead of Fed
The UK blue-chip index closed nearly four points higher at 7,511
A sixth sense for biotech helps Arix Bioscience turn risk into profit as portfolio value nearly doubles
Analysts at Stifel say the venture capital firm is entering its first extended period of sustained news flow with shares trading at about 45% discount to their £2.53 price target
Arix Biosciences’ investee company Iterum kicks off phase III trials of next-generation antibiotic
Unlike most penem drugs, Iterum’s sulopenem can be taken orally, which is why analysts think it has the potential to become a blockbuster antibiotic drug
Pharmaxis adds valuable experience with Ed Rayner appointment
Ed Rayner is an investment director for major shareholder Arix Bioscience Plc (LSE:ARIX).
Archive
Proactive news snapshot: Bushveld Minerals, Nektan. Europa Metals …
A glance at some of the day's highlights from the Proactive Investors newswire
Anglo Asian Mining shares fly higher as it takes steps to identify new targets
A look at some of the top risers and fallers in London on Thursday
FTSE 100 finishes lower as BoE keeps rates on hold; sterling gains
The UK benchmark index of leading shares finished down nearly 32 points at 7,281
Greatland Gold jumps on upbeat rock chip results from Black Hills licence in Australia
A look at some of the biggest risers and fallers on the London market this Tuesday
Archive
Proactive news snapshot: European Metals Holdings, Regency Mines, OptiBiotix Health …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Bioscience CEO to transition into new role in preparation for next stage of growth
Joe Anderson’s venture capital background made him an ideal fit for the CEO role during Arix’s early years, but the time has come for a new face to take the firm through its next stage of growth
FTSE 100 closes in red as BoE governor Carney could stay on and WPP plunges
Economists at ING said the August manufacturing data suggests “US business is weathering the protectionist storm for now"
Pharmaxis gains Arix Bioscience Plc as a new substantial shareholder
Arix led a $24 million share placement and will invest $14.2 million in two tranches.
Arix Bioscience share sale explains recent market disconnect, say brokers
Chris Chipperton, a founder of the company, sold 3mln shares or around a third of his stake at 155p
Archive
Proactive news snapshot: SDX Energy, Victoria Oil & Gas, Motif Bio …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Philip Hammond’s online tax comments hit ASOS, BooHoo and JustEat
A look at some of the top risers and fallers in London today
Archive
Proactive news snapshot: Arix Bioscience, RM Secured Direct Lending, Diversified Gas & Oil …
A glance at some of the day's highlights from the Proactive Investors newswire
Arix Biosciences making progress as well as adding value
Three of Arix's investee companies will be busy in the coming months, while a fourth now has the financial runway to expand its ground-breaking research
Investments and investor services
FTSE 100 set to end the week in volatility as metal tariffs hit Turkish lira
The quarterly update on the health of the UK economy showed something of a recovery from the snowed under first quarter.
Archive
Proactive news snapshot: Solo Oil, Metal Tiger, Tekcapital …
A glance at some of the day's highlights from the Proactive Investors newswire
IWG and Sabien Technology among Monday’s market losers
A look at some of the top risers and fallers in London today
Arix Bioscience takes stake in Aussie fibrosis specialist Pharmaxis
Arix led a A$24mln (£13.4mln) primary placing and will invest A$14.2mln itself in two tranches
Investments and investor services
FTSE 100 closes higher, supported by gains in oil giants as crude prices rise
At the close, the UK blue chip index was 4.68 points higher at 7,663.78, just below the session peak of 7,681.86, having recovered from a low of 7,636.60
Investments and investor services
Pharmaxis secures $24 million at premium to support partnering negotiations
The capital raising was priced at a premium to the last traded share price.
Arix Biosciences' progress significantly undervalued, suggests US broker
Arix’s portfolio companies are involved in 15 clinical trials
Archive
Arix Bioscience lifts net assets by 76% as two companies list on Nasdaq
Cancer pioneer Autolus and anti-infective group Iterum both floated in the US
Arix Bioscience price target raised after successful Autolus float
Arix is trading at a discount even to the estimated half-year net asset value of 180p
Cancer biotech company Autolus Therapeutics raises US$150mln in IPO
The IPO price was at the upper end of the US$15 to US$17 range
Arix Bioscience shares jump as largest investee firm Autolus files for proposed US IPO
Autolus, which was spun out from University College London in 2014, is aiming to develop next-generation CAR-T treatments that it hopes will have an edge over the first wave of anti-cancer therapies
Nanoco Group on the front foot after receiving £1.8mln payment from US partner
A look at some of the top risers and fallers in London on Tuesday
Archive
Lloyds, Barclays, RBS, GSK and Shire kick off earnings season for banks and pharmas
The week ahead in includes updates from Lloyds, Barclays, RBS, Shire, GSK, Whitbread, Persimmon and Shell
Archive
Banks to dominate another busy earnings week, including numbers from HSBC and RBS
Week ahead: HSBC, Royal Bank of Scotland, Royal Dutch Shell, Next, Centrica, Shire, US jobs, Bank of England policy meeting ...
Arix Bioscience hoping to generate venture capital-style returns from the life sciences industry
Arix isn’t a fund and it certainly isn’t a traditional VC, although in a lot of ways it operates like one.
SyndicateRoom to support £100mln IPO of Downing Strategic Micro-Cap Trust
SyndicateRoom will offer shares in DSM to its members on the same terms as the institutional investors
Archive
Proactive news round-up: Tern, Jersey Oil & Gas, European Metals Holdings …
A glance at some of the stories on the Proactive newswire today
Metal Tiger runs into profit-taking; Brave Bison downed by warning
The main risers and fallers around 2.45pm included Brave Bison, Metal Tiger, PCG, Entertainment ...
Investments and investor services
FTSE 100 ends higher as food groups power gains on takeover battle
Around 3.15pm, the UK blue chip index was up over 21 points at 7,299, not far from the day’s peak of 7,307, and well above the day’s low of 7,253.